BACKGROUND: Low-grade fibromyxoid sarcoma (LGFMS) is a rare sarcoma subtype with a generally indolent pattern of clinical behaviour, but treatments for advanced disease are limited. PATIENTS AND METHODS: A retrospective search of a prospectively maintained institutional database identified 102 patients treated from December 1994 to August 2018. We evaluated the outcome of patients and the efficacy and safety of non-surgical therapies in LGFMS. RESULTS: Ninety-four out of 102 (92.2%) underwent primary resection, seven (6.9%) were treated with systemic therapy and one (1.0%) is currently being treated with pre-operative radiotherapy. The RECIST 1.1 response rate to first-line chemotherapy was 0%, and median progression-free survival was 1.84 months (95% confidence intervaI=0.10-3.6 months). CONCLUSION: Conventional systemic therapy has limited efficacy in advanced LGFMS. Copyright
BACKGROUND: Low-grade fibromyxoid sarcoma (LGFMS) is a rare sarcoma subtype with a generally indolent pattern of clinical behaviour, but treatments for advanced disease are limited. PATIENTS AND METHODS: A retrospective search of a prospectively maintained institutional database identified 102 patients treated from December 1994 to August 2018. We evaluated the outcome of patients and the efficacy and safety of non-surgical therapies in LGFMS. RESULTS: Ninety-four out of 102 (92.2%) underwent primary resection, seven (6.9%) were treated with systemic therapy and one (1.0%) is currently being treated with pre-operative radiotherapy. The RECIST 1.1 response rate to first-line chemotherapy was 0%, and median progression-free survival was 1.84 months (95% confidence intervaI=0.10-3.6 months). CONCLUSION: Conventional systemic therapy has limited efficacy in advanced LGFMS. Copyright
Authors: Axel Le Cesne; Sara Cresta; Robert G Maki; Jean Yves Blay; Jaap Verweij; Andrés Poveda; Paolo G Casali; Carme Balaña; Patrick Schöffski; Federica Grosso; Pilar Lardelli; Antonio Nieto; Vicente Alfaro; George D Demetri Journal: Eur J Cancer Date: 2012-06-29 Impact factor: 9.162
Authors: Fredrik Mertens; Christopher D M Fletcher; Cristina R Antonescu; Jean-Michel Coindre; Maurizio Colecchia; Henryk A Domanski; Erinn Downs-Kelly; Cyril Fisher; John R Goldblum; Louis Guillou; Robin Reid; Juan Rosai; Raf Sciot; Nils Mandahl; Ioannis Panagopoulos Journal: Lab Invest Date: 2005-03 Impact factor: 5.662
Authors: Brian O'Sullivan; Aileen M Davis; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Rita Kandel; Karen Goddard; Anna Sadura; Joseph Pater; Benny Zee Journal: Lancet Date: 2002-06-29 Impact factor: 79.321
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Salvatore Provenzano; Alessandra Raimondi; Rossella M Bertulli; Vittoria Colia; Salvatore L Renne; Paola Collini; Gianpaolo Dagrada; Dario Callegaro; Marco Fiore; Francesca G Greco; Paolo G Casali Journal: Clin Sarcoma Res Date: 2017-12-28